The Experts below are selected from a list of 99 Experts worldwide ranked by ideXlab platform
Timothy J. Schroeder - One of the best experts on this subject based on the ideXlab platform.
-
Immunological monitoring in cyclosporine-treated patients.
Clinical Biochemistry, 1991Co-Authors: Rachel M Mckenna, Timothy J. SchroederAbstract:The immunosuppressive action of cyclosporine (CsA) in vivo is thought to primarily involve its inhibitory effect on Lymphokine production by T lymphocytes. Most efforts to assess immunosuppression in CsA-treated patients have concentrated on measuring some aspect of activated T cell function. These have included monitoring of lymphocyte subsets and the appearance of activated T cell markers, assaying the production of Lymphokines and the direct measurement of Lymphokines in serum and urine, and most recently measurement of soluble Interleukin-2 receptor (SIL2R). Using a new microparticle enzyme immunoassay (MEIA) in a preliminary study of 12 CsA-treated renal transplant recipients, we found significant increases in serum SIL2R levels in patients with rejection and we conclude that MEIA may have some use in the monitoring of CsA-treated patients.
-
Immunological monitoring in cyclosporine-treated patients.
Clinical Biochemistry, 1991Co-Authors: Rachel M Mckenna, Timothy J. SchroederAbstract:The immunosuppressive action of cyclosporine (CsA) in vivo is thought to primarily involve its inhibitory effect on Lymphokine production by T lymphocytes. Most efforts to assess immunosuppression in CsA-treated patients have concentrated on measuring some aspect of activated T cell function. These have included monitoring of lymphocyte subsets and the appearance of activated T cell markers, assaying the production of Lymphokines and the direct measurement of Lymphokines in serum and urine, and most recently measurement of soluble Interleukin-2 receptor (SIL2R). Using a new microparticle enzyme immunoassay (MEIA) in a preliminary study of 12 CsA-treated renal transplant recipients, we found significant increases in serum SIL2R levels in patients with rejection and we conclude that MEIA may have some use in the monitoring of CsA-treated patients.
Rachel M Mckenna - One of the best experts on this subject based on the ideXlab platform.
-
Immunological monitoring in cyclosporine-treated patients.
Clinical Biochemistry, 1991Co-Authors: Rachel M Mckenna, Timothy J. SchroederAbstract:The immunosuppressive action of cyclosporine (CsA) in vivo is thought to primarily involve its inhibitory effect on Lymphokine production by T lymphocytes. Most efforts to assess immunosuppression in CsA-treated patients have concentrated on measuring some aspect of activated T cell function. These have included monitoring of lymphocyte subsets and the appearance of activated T cell markers, assaying the production of Lymphokines and the direct measurement of Lymphokines in serum and urine, and most recently measurement of soluble Interleukin-2 receptor (SIL2R). Using a new microparticle enzyme immunoassay (MEIA) in a preliminary study of 12 CsA-treated renal transplant recipients, we found significant increases in serum SIL2R levels in patients with rejection and we conclude that MEIA may have some use in the monitoring of CsA-treated patients.
-
Immunological monitoring in cyclosporine-treated patients.
Clinical Biochemistry, 1991Co-Authors: Rachel M Mckenna, Timothy J. SchroederAbstract:The immunosuppressive action of cyclosporine (CsA) in vivo is thought to primarily involve its inhibitory effect on Lymphokine production by T lymphocytes. Most efforts to assess immunosuppression in CsA-treated patients have concentrated on measuring some aspect of activated T cell function. These have included monitoring of lymphocyte subsets and the appearance of activated T cell markers, assaying the production of Lymphokines and the direct measurement of Lymphokines in serum and urine, and most recently measurement of soluble Interleukin-2 receptor (SIL2R). Using a new microparticle enzyme immunoassay (MEIA) in a preliminary study of 12 CsA-treated renal transplant recipients, we found significant increases in serum SIL2R levels in patients with rejection and we conclude that MEIA may have some use in the monitoring of CsA-treated patients.
Michael T. Halpern - One of the best experts on this subject based on the ideXlab platform.
-
Human nonspecific suppressive Lymphokines
Journal of Clinical Immunology, 1991Co-Authors: Michael T. HalpernAbstract:Since the term “Lymphokine” first appeared in print over 20 years ago, a tremendous number of these soluble mediators of the immune system have been described. Within the past few years, many human nonspecific suppressive Lymphokines have been identified. This review discusses the historical basis of immunologic suppression and suppressor factors. Later reports describing suppressive human Lymphokines are then grouped into four categories: primarily stimulatory Lymphokines that also mediate certain suppressive activities, suppressive Lymphokines produced during altered states of immunity, suppressive Lymphokines produced by exogenously stimulated lymphocytes, and suppressive Lymphokines produced by unstimulated lymphocytes. Recent work I have been involved in focusing on the human suppressive Lymphokine soluble suppressor factor (SSF) is also discussed.
Ronald H Schwartz - One of the best experts on this subject based on the ideXlab platform.
-
cd4 and cd8 t cells acquire specific Lymphokine secretion potentials during thymic maturation
Nature, 1991Co-Authors: Albert Bendelac, Ronald H SchwartzAbstract:Peripheral CD4+ and CD8+ T lymphocytes carry out different functions during immune reactions, partly as a result of the distinct patterns of Lymphokines that they secrete upon stimulation. Using thymic cells from adult and newborn mice as well as from fetal organ cultures, we show here that this functional differentiation occurs inside the thymus and is completed during the single positive stage by the time the T-cell receptor becomes fully coupled to the intracellular activation pathways leading to Lymphokine secretion. Surprisingly, CD4+8- thymocytes differ from their immediate progeny, naive peripheral CD4+ cells, in that they secrete a broader range of Lymphokines, including interleukins 4, 5 and 10 and gamma-interferon, and more closely resemble immunologically experienced (activated or memory) CD4+ lymphocytes.
A Kelso - One of the best experts on this subject based on the ideXlab platform.
-
Quantitative analysis of Lymphokine expression in vivo and in vitro.
Immunology and cell biology, 1992Co-Authors: A B Troutt, E Maraskovsky, L A Rogers, M H Pech, A KelsoAbstract:Constitutive Lymphokine production by cells isolated from mice injected with keyhole limpet haemocyanin (KLH) or from mice undergoing an acute graft vs host reaction (GVHR) was very low, but could be markedly increased by T cell receptor (TCR) ligation. This suggested that in vivo levels of Lymphokine production are much lower than those induced by in vitro stimulation. Serum Lymphokine titres were consistent with this possibility, and analysis of Lymphokine mRNA levels using S1-nuclease protection demonstrated that in vitro-stimulated cells from normal, KLH and GVHR mice all had markedly increased levels of Lymphokine transcripts relative to levels found in vivo. A novel method combining limiting dilution analysis with polymerase chain reaction amplification of cDNA was developed that showed that these differences in levels of Lymphokine production were due at least in part to differences in the frequencies of Lymphokine mRNA-containing cells. Studies of the means by which differential Lymphokine production is achieved demonstrated that CD4+, CD8+ and cytotoxic T lymphocyte (CTL) clones all express a common, restricted set of Lymphokines in response to a defined in vitro stimulus, but that individual in vivo primed cells can express at least seven distinct patterns of Lymphokine production.
